3-Heptanone as a potential new marker for valproic acid therapy
3-Heptanone as a potential new marker for valproic acid therapy
复制标题
DOI：
10.1088/1752-7155/3/1/016004
复制
发表时间：
2009-03-01
影响因子：
3.8
通讯作者：
Scholl-Buergi, S.
中科院分区：
文献类型：
--
作者：
Erhart, S.;Amann, A.;Scholl-Buergi, S.
通过质子转移反应质谱法筛选来自27名癫痫患者（17名男性和10名女性患者;平均年龄：9.7岁，中位年龄：8.2岁，SD：+/- 4.2岁）的呼吸气体样本。患者接受丙戊酸（VPA）治疗，并采集血样测定VPA浓度。所有患者呼出气体中3-庚酮（C（7）H（14）O）浓度均显著升高（平均值：14.7 ppb，中位数：13.8 ppb，标准差：+/- 5.7 ppb）。在人类的呼吸中，可以检测到数百种不同的挥发性有机化合物。在丙戊酸单药治疗患者的呼吸中，测量到3-庚酮浓度增加。本研究的目的是研究血清VPA浓度是否与呼出气中的3-庚酮浓度相关。总之，在接受丙戊酸治疗的患者中，呼吸气体中的3-庚酮显著升高，但与血清中的VPA浓度或该药物的每日剂量无显著相关性。
Breath gas samples from 27 patients with epilepsy (17 male and 10 female patients; mean age: 9.7 years, median age: 8.2 years, SD: +/- 4.2 years) were screened via proton transfer reaction mass spectrometry. The patients were treated with valproic acid (VPA) therapy, and blood samples for determination of VPA concentrations were surveyed. All patients showed significantly elevated concentrations of 3-heptanone (C(7)H(14)O) in exhaled breath gas (mean: 14.7 ppb, median: 13.8 ppb SD: +/- 5.7 ppb). In human breath, several hundred different volatile organic compounds can be detected. In breath of patients with valproic acid monotherapy, an increased concentration of 3-heptanone was measured. The objective of this study was to investigate if serum VPA concentrations correlate with 3-heptanone concentrations in exhaled breath. In conclusion, 3-heptanone in breath gas is significantly elevated in patients treated with the valproic acid, but does not correlate significantly with the VPA concentrations in serum or the daily dose of this drug.